Health & Environmental Research Online (HERO)


Print Feedback Export to File
7069457 
Journal Article 
A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity 
Skorko, A; Marinelli, L; Balestrino, M; Mori, L; Puce, L; Rosa, GM; Giorello, L; Currà, A; Fattapposta, F; Serrati, C; Gandolfo, C; Abbruzzese, G; Trompetto, C; , 
2017 
1 
BMJ Open
EISSN: 2044-6055 
BMJ PUBLISHING GROUP 
LONDON 
English 
28882919 
WOS:000412650700165 
Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being considered useful also in the treatment of pain, nausea and epilepsy, but may bear and increased risk for cardiovascular events. Spasticity is often assessed with subjective and clinical rating scales, which are unable to measure the increased excitability of the monosynaptic reflex, considered the hallmark of spasticity. The neurophysiological assessment of the stretch reflex provides a precise and objective method to measure spasticity. We propose a novel study to understand if Sativex could be useful in reducing spasticity in stroke survivors and investigating tolerability and safety by accurate cardiovascular monitoring.